Cargando…

High Throughput Screening for Small Molecule Therapy for Gaucher Disease Using Patient Tissue as the Source of Mutant Glucocerebrosidase

Gaucher disease (GD), the most common lysosomal storage disorder, results from the inherited deficiency of the lysosomal enzyme glucocerebrosidase (GCase). Previously, wildtype GCase was used for high throughput screening (HTS) of large collections of compounds to identify small molecule chaperones...

Descripción completa

Detalles Bibliográficos
Autores principales:	Goldin, Ehud, Zheng, Wei, Motabar, Omid, Southall, Noel, Choi, Jae Hyuk, Marugan, Juan, Austin, Christopher P., Sidransky, Ellen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260169/ https://www.ncbi.nlm.nih.gov/pubmed/22272254 http://dx.doi.org/10.1371/journal.pone.0029861

Ejemplares similares

High Throughput Screening for Inhibitors of Alpha-Galactosidase
por: Motabar, Omid, et al.
Publicado: (2010)

Chaperoning glucocerebrosidase: a therapeutic strategy for both Gaucher disease and Parkinsonism
por: McMahon, Benjamin, et al.
Publicado: (2016)

Fabry Disease – Current Treatment and New Drug Development
por: Motabar, Omid, et al.
Publicado: (2010)

Glucocerebrosidase and its relevance to Parkinson disease
por: Do, Jenny, et al.
Publicado: (2019)

Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease
por: Galper, Jasmin, et al.
Publicado: (2021)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
por: Furderer, Makaila L., et al.
Publicado: (2022)

Analysis of glucocerebrosidase (GBA) gene mutations in Iranian patients with Gaucher disease
por: MOZAFARI, Hadi, et al.
Publicado: (2021)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease
por: Westbroek, Wendy, et al.
Publicado: (2016)

Small Molecule Chaperones for the Treatment of Gaucher Disease and GBA1-Associated Parkinson Disease
por: Han, Tae-Un, et al.
Publicado: (2020)

Progranulin Recruits HSP70 to β-Glucocerebrosidase and Is Therapeutic Against Gaucher Disease
por: Jian, Jinlong, et al.
Publicado: (2016)

Characterization of Novel Human β-glucocerebrosidase Antibodies for Parkinson Disease Research
por: Jong, Tiffany, et al.
Publicado: (2023)

The Spectrum of Neurological Manifestations Associated with Gaucher Disease
por: Roshan Lal, Tamanna, et al.
Publicado: (2017)

Lysosomal storage and impaired autophagy lead to inflammasome activation in Gaucher macrophages
por: Aflaki, Elma, et al.
Publicado: (2015)

Identification of novel mutations in glucocerebrosidase (GBA) gene in Indian patients with gaucher disease (GD)
por: Ankleshwaria, Chitra, et al.
Publicado: (2014)

Pharmacological Chaperones and Coenzyme Q(10) Treatment Improves Mutant β-Glucocerebrosidase Activity and Mitochondrial Function in Neuronopathic Forms of Gaucher Disease
por: de la Mata, Mario, et al.
Publicado: (2015)

High-Throughput Multiplexed Quantitation of Protein Aggregation and Cytotoxicity in a Huntington’s Disease Model
por: Titus, Steven A, et al.
Publicado: (2012)

A High Throughput Screening Assay System for the Identification of Small Molecule Inhibitors of gsp
por: Bhattacharyya, Nisan, et al.
Publicado: (2014)

Two phosphatidylinositol 4-kinases control lysosomal delivery of the Gaucher disease enzyme, β-glucocerebrosidase
por: Jović, Marko, et al.
Publicado: (2012)

Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase
por: Bendikov-Bar, Inna, et al.
Publicado: (2013)

Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson’s Disease
por: Kopytova, Alena E., et al.
Publicado: (2023)

Efferocytosis is impaired in Gaucher macrophages
por: Aflaki, Elma, et al.
Publicado: (2017)

Functionalized Cyclophellitols Are Selective Glucocerebrosidase Inhibitors and Induce a Bona Fide Neuropathic Gaucher Model in Zebrafish
por: Artola, Marta, et al.
Publicado: (2019)

Targeted Enzymatic VLP‐Nanoreactors with β‐Glucocerebrosidase Activity as Potential Enzyme Replacement Therapy for Gaucher's Disease
por: Chauhan, Kanchan, et al.
Publicado: (2022)

Gaucher disease in the COVID-19 pandemic environment: The good, the bad and the unknown
por: Ginns, Edward I., et al.
Publicado: (2021)

In silico identification of genetic variants in glucocerebrosidase (GBA) gene involved in Gaucher's disease using multiple software tools
por: Manickam, Madhumathi, et al.
Publicado: (2014)

Rapid-Onset Dystonia and Parkinsonism in a Patient With Gaucher Disease
por: Hertz, Ellen, et al.
Publicado: (2023)

Bilateral femoral osteolytic lesions in a patient with type 3 Gaucher disease
por: Teefe, Enock, et al.
Publicado: (2015)

The appearance of newly identified intraocular lesions in Gaucher disease type 3 despite long-term glucocerebrosidase replacement therapy
por: Sawicka-Gutaj, Nadia, et al.
Publicado: (2016)

Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits
por: Sun, Ying, et al.
Publicado: (2010)

Endoplasmic Reticulum Ca(2+) Increases Enhance Mutant Glucocerebrosidase Proteostasis
por: Ong, Derrick Sek Tong, et al.
Publicado: (2010)

Polymorphisms in the glucocerebrosidase gene and pseudogene urge caution in clinical analysis of Gaucher disease allele c.1448T>C (L444P)
por: Brown, Justin T, et al.
Publicado: (2006)

Probing the Inhibitor versus Chaperone Properties of sp(2)-Iminosugars towards Human β-Glucocerebrosidase: A Picomolar Chaperone for Gaucher Disease
por: Mena-Barragán, Teresa, et al.
Publicado: (2018)

A high-throughput screening to identify small molecules that suppress huntingtin promoter activity or activate huntingtin-antisense promoter activity
por: Khaled, Houda G., et al.
Publicado: (2021)

Clinical course and prognosis in patients with Gaucher disease and parkinsonism
por: Lopez, Grisel, et al.
Publicado: (2016)

The definition of neuronopathic Gaucher disease
por: Schiffmann, Raphael, et al.
Publicado: (2020)

Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS
por: Bendikov-Bar, Inna, et al.
Publicado: (2014)

Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency
por: Gatto, Emilia M., et al.
Publicado: (2019)

Parkinsonism Associated with Glucocerebrosidase Mutation
por: Sunwoo, Mun-Kyung, et al.
Publicado: (2011)

Glucocerebrosidase mutations in primary parkinsonism
por: Asselta, Rosanna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v78elqkh5h0bgfhb4h6civg8ee